Prostate Cancer Conference Highlights from ASCO GU 2025 - Takeaways - MDSpire

Prostate Cancer Conference Highlights from ASCO GU 2025

The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the prostate cancer clinical updates you need to know from GU ASCO 2025. This video highlights updates in mCRPC and oligometastatic prostate cancer trials.

  • March 3, 2025

Share

  • 1

    The TALAPRO-2 study shows that talazoparib plus enzalutamide improves overall survival in metastatic castrate-resistant prostate cancer.

  • 2

    The ENZA-P trial demonstrates that 177LuPSMA combined with enzalutamide enhances radiographic progression-free survival and quality of life in mCRPC.

  • 3

    The WOLVERINE meta-analysis indicates that metastasis-directed therapy benefits patients with oligometastatic prostate cancer.

  • 4

    Genomic testing is essential to identify patients who may benefit from combination PARP inhibitors in prostate cancer treatment.

  • 5

    The combination of talazoparib and enzalutamide has high rates of adverse events, necessitating careful patient selection.

Original Source(s)

Prostate Cancer Conference Highlights from ASCO GU 2025

  • March 3, 2025

Related Content

Retraction: MicroRNA-935 directly targets FZD6 to inhibit the proliferation of human glioblastoma and correlate to glioma malignancy and prognosis

  • May 28, 2026

Differentiation of hepatocellular carcinoma from hepatic hemangioma using diffusion-derived vessel density map-based radiomics features

Prospective phase II study of frontline Helicobacter pylori eradication therapy for early-stage extragastric mucosa-associated lymphoid tissue lymphoma